Stock listing

NASDAQ:RTSN Retension Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Retension Pharmaceuticals, Inc.

Follow Retension Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RTSN

$10.51 USD -2.50 (-19.2%)

Close on Nov 20, 2026

Past month -12.4% · daily closes, Oct 8, 2026 – Nov 20, 2026, adjusted for splits
Day range
$9.23 – $13.10 USDNov 20, 2026
Volume
162,742 sharesNov 20, 2026
Market cap
$87.57M USDAt the close on Nov 20, 2026 · price × 8.33M shares outstanding
Traded on an average day
$1.74M USDMedian day 103,606 shares · 1 day with no trades · last 3 months, Oct 8, 2026 – Nov 20, 2026
Retension Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RTSN · Home$10.51 USD-2.50 (-19.2%)162,742$12.80$13.10$9.23$13.01Close on Nov 20, 2026

Daily closes

Last 3 months, Oct 8, 2026 – Nov 20, 2026 · NASDAQ:RTSN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.51-2.50-19.2%$12.80$13.10$9.23162,742
$13.01-0.88-6.3%$13.86$13.92$12.6154,566
$13.89+2.48+21.7%$11.45$14.16$11.45108,911
$11.41-0.05-0.4%$11.37$11.88$10.2544,129
$11.46-0.81-6.6%$12.20$12.34$10.25320,854
$12.27+0.02+0.2%$12.30$12.70$11.37125,000
$12.25+0.10+0.8%$11.79$12.40$11.6394,400
$12.15+0.13+1.1%$11.89$12.40$11.5991,500
$12.02-0.37-3.0%$12.16$12.77$11.03248,100
$12.39+1.35+12.2%$10.96$12.83$10.31306,400
$11.04+0.32+3.0%$10.62$11.19$10.5429,400
$10.72-0.88-7.6%$11.33$11.80$10.43114,400
$11.60-0.19-1.6%$12.18$12.80$11.40153,000
$11.79+0.49+4.3%$11.07$12.25$11.0781,500
$11.30-0.06-0.5%$11.44$13.03$11.2071,300
$11.36-0.47-4.0%$11.76$11.76$10.8558,700
$11.83-1.26-9.6%$12.95$12.97$11.3045,100
$13.09-0.43-3.2%$13.44$13.90$12.1967,300
$13.52-0.72-5.1%$14.40$14.60$12.7075,300
$14.24-1.01-6.6%$15.13$15.82$14.2447,200
$15.25-0.25-1.6%$15.85$16.29$14.5977,900
$15.50+0.50+3.3%$14.81$16.00$14.07121,100
$15.00-1.18-7.3%$16.18$18.19$14.29110,600
$16.18-0.15-0.9%$16.53$17.40$15.1198,300
$16.33+2.26+16.1%$14.14$18.64$14.10267,200
$14.07+1.86+15.2%$12.21$14.97$12.17208,900
$12.21+0.57+4.9%$11.56$12.86$11.56131,000
$11.64+0.01+0.1%$11.63$12.25$11.0077,200
$11.63+0.31+2.7%$11.83$12.50$11.41137,600
$11.32+0.79+7.5%$10.88$11.79$10.16173,900
$10.53-1.47-12.3%$10.00$11.60$9.66789,200
$12.00——$12.00$12.00$12.000
Ticker
NASDAQ:RTSN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Retension Pharmaceuticals, Inc. news

Retension Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in the last 12 months · 2 in all · newest Nov 18, 2026 · oldest 2026

Where Retension Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RTSN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:RTSNBOATSUnited StatesUSD
Frankfurt:TL4FrankfurtGermanyEUR
Hamburg:TL4HamburgGermanyEUR
Munich:TL4MunichGermanyEUR

Valuation

Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$78.38M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Retension Pharmaceuticals, Inc. · NASDAQ:RTSNUS$87.57MUS$78.38Mn/an/an/an/an/an/an/a
Infant Bacterial Therapeutics AB Class B · OMXSTO:IBT_BUS$88.42MUS$77.79Mn/an/an/a17.0×n/a0.0×n/a
Bio Solution Co., Ltd. · KRX:086820US$88.40MUS$79.76M137×6.2×n/a2.9×5.0%0.0×n/a
Y-Biologics Inc. · KRX:338840US$87.59MUS$70.94Mn/a30.1×n/a6.8×n/a0.9×n/a
Cumberland Pharmaceuticals Inc. · NASDAQ:CPIXUS$87.57MUS$11.59M1.3×0.5×n/a1.2×273.7%0.1×0.72
Equillium, Inc. · NASDAQ:EQUS$87.26MUS$34.71Mn/an/an/a1.7×n/a0.0×1.31
Upstream Bio, Inc. · NASDAQ:UPBUS$87.15M−US$119.4Mn/a−41.6×n/a0.4×n/a0.0×1.95
Senhwa Biosciences Inc · TPEX:6492US$86.77MUS$67.44Mn/a2,117×n/a4.6×n/a0.0×n/a
Bioceltix SA · GPW:BCXUS$86.32MUS$72.37Mn/an/an/a5.6×n/a0.0×n/a
Perspective Therapeutics, Inc. · AMEX:CATXUS$86.05M−US$114.1Mn/a−570×n/a0.3×n/a0.0×1.47
Pharmosa Biopharm Inc. · TPEX:6875US$86.04MUS$62.27Mn/a38.5×n/a2.1×−658.1%0.1×n/a
Median of the othersUS$87.21MUS$64.86M69.1×6.2×2.5×5.0%0.0×1.39

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
51.67 USD · Analysts' mean
EPS, year to Dec 2026
-2.60 · 1 analyst

Team and board

Officers

OfficerRole
Eric KellerChief Executive Officer, Co-Founder & Chairman
Alex SchwartzChief Financial Officer
Sabine BissonChief Operating Officer
Kevin SchutzVice President, Regulatory Affairs
LeAnne BloedonExecutive Vice President, Clinical Development and Operations
Alison D. SchecterChief Medical Officer
Paul SweetnamChief Scientific Officer & Co-Founder

Board

DirectorRole
Eric KellerChief Executive Officer, Co-Founder & Chairman
Donald OldsDirector
Franklin BergerDirector
Pavan CheruvuDirector

Events

QuarterResultsShare move
Q3 2026Nov 18, 2026+14.0%

Open Events

IPO

Priced at US$12.00 a share on Oct 8, 2026.

Price
US$12.00 a share
Shares offered
3,750,000 shares of common stock
Offering size
US$45 million
Underwriters' option
Up to 562,500 more shares
Listing
RTSN on the Nasdaq Capital Market
Underwriters
Leerink Partners, Guggenheim Securities, Oppenheimer & Co., Titan Partners · In the order on the cover
Shares delivered
On or about Oct 13, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 17, 2026
Filed publiclySep 18, 2026
Amended twiceNewest Oct 7, 2026
Shares registered with an exchangeOct 8, 2026
Declared effective by the SECOct 8, 2026
Final prospectus, with the priceOct 9, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Oct 9, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development5.11M1.30M
Selling, general and administrative1.77M976.4K
Operating income-6.88M-2.28M
Income before tax-6.30M-1.91M
Net income-6.30M-1.91M
Earnings per share, basic-0.76-0.23

Balance sheet

LineFY2025FY2024
Cash and equivalents18.9M8.19M
Current assets21.4M8.37M
Total assets21.4M8.37M
Accounts payable775.9K194.4K
Current liabilities912.2K277.0K
Total liabilities29.2M10.1M
Shareholders' equity-7.78M-1.73M
Shares outstanding8.33M8.33M

Cash flow

LineFY2025FY2024
Cash from operations-7.78M-1.76M
Capital spending00
Free cash flow-7.78M-1.76M
Cash from financing18.5M3.61M
Change in cash10.7M1.86M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 18, 2026Quarterly reportSEC
8-K · Current reportNov 18, 2026ResultsSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
8-K · Current reportOct 22, 2026Management or board changeSEC
3 · Initial statement of ownershipOct 16, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2026Big-stake noticeSEC
All 47 filings
FilingDateTypeFiled with
SCHEDULE 13D · Big-stake noticeOct 14, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansOct 14, 2026Offer documentSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 13, 2026Insider tradeSEC
8-K · Current reportOct 13, 2026Current reportSEC
424B4 · ProspectusOct 9, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 9, 2026Other filingsSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringOct 8, 2026Offer documentSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
CERT · Exchange's certificate of listingOct 8, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 8, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 7, 2026Offer documentSEC
S-1/A · Registration statement, amendedOct 5, 2026Offer documentSEC
S-1 · Registration statementSep 18, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedAug 14, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJun 16, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedApr 30, 2026Offer documentSEC
DRS · Draft registration statementFeb 17, 2026Offer documentSEC
DMay 6, 2025Other filingsSEC
D/AMay 15, 2024Other filingsSEC
DDec 5, 2023Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Retension Pharmaceuticals, Inc.’s releases

Common shares
8,331,599
Fully diluted
8,331,599

Fully diluted

LineShares
Common shares8,331,599

Share count over time

CountShares
Nov 22, 20268,331,599

Open Cap table

Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Berger Franklin M
Director
Buy10,000USD 12.00US$120KOct 13, 2026
Keller Eric L.
Director, Officer: CHIEF EXECUTIVE OFFICER
Buy20,800USD 12.00US$250KOct 13, 2026

Big stakes

HolderStakeSharesDate
B Group, Inc.10.00%833KOct 13, 2026
Pvg Asset Management Corp8.30%1MOct 9, 2026
Laurence W. Lytton7.40%617KOct 13, 2026
Eric Keller7.07%599KOct 13, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Franklin Berger
Other companies: Atea Pharmaceuticals, Inc. (Director · Since at least Oct 29, 2020); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 29, 2020 · Past); Immune Design Corp (Director · Jul 23, 2014 – Apr 2, 2019 · Past); Five Prime Therapeutics Inc (Director · Sep 17, 2013 – Apr 16, 2021 · Past); Lineage Cell Therapeutics, Inc. (Director · May 13, 2013 – Aug 20, 2013 · Past); Emisphere Technologies Inc (Director · May 15, 2009 – May 15, 2009 · Past); Seagen Inc (Director · May 19, 2006 – Feb 21, 2014 · Past)
Director · Since at least Oct 13, 2026
Pavan Cheruvu
Other companies: Amanat Acquisition Corp (Chief Executive Officer, Director · Since at least May 18, 2026); Sio Gene Therapies Inc (Chief Executive Officer, Director · Feb 11, 2018 – Dec 8, 2021 · Past)
Director · Since at least Nov 5, 2026
Donald Olds
Other companies: Grace Therapeutics, Inc. (Director · Apr 1, 2020 – Aug 31, 2023 · Past)
Director · Since at least Oct 13, 2026
Michael J Berendt
Other companies: Waters Corporation (Director · May 15, 2013 – Aug 13, 2021 · Past)
Director · Since at least Oct 13, 2026
Alex SchwartzChief Financial Officer · Since at least Nov 4, 2026
Alison D. SchecterChief Medical Officer · Since at least Nov 4, 2026
Eric KellerCHIEF EXECUTIVE OFFICER, Director · Since at least Oct 13, 2026
Kevin SchutzVice President, Regulatory Affairs · Since at least Nov 4, 2026
LeAnne BloedonExecutive Vice President, Clinical Development and Operations · Since at least Nov 4, 2026
Paul SweetnamCHIEF SCIENTIFIC OFFICER · Since at least Oct 13, 2026
All 11 people
PersonSeat
Sabine BissonCHIEF OPERATING OFFICER · Since at least Oct 13, 2026

Open People

Log in to ask 6ix AI your own questions about Retension Pharmaceuticals, Inc.